Table of Contents
- Abemaciclib Overview
- Specifications & Comparative Analysis
- Therapeutic Applications
- Clinical Usage Guidelines
- Clinical Case Studies
- Contact for Pharmaceutical Procurement
Abemaciclib (CAS 1231929-97-7) Overview
Chemical Profile
| Parameter | Description |
|---|---|
| CAS Number | 1231929-97-7 |
| Molecular Formula | C27H32N8O |
| Molecular Weight | 480.6 g/mol |
| Appearance | White to yellow crystalline powder |
| Storage | 2-8°C protected from light |
Comparative Analysis of CDK4/6 Inhibitors
| Parameter | Abemaciclib | Palbociclib | Ribociclib |
|---|---|---|---|
| Bioavailability | 45% | 46% | 60-70% |
| Half-life | 18.3h | 29h | 32.0h |
| Dosing Frequency | Twice daily | Once daily | Once daily |
| FDA Approval | 2017 | 2015 | 2017 |
Therapeutic Applications
Primary Indications
- HR+/HER2- advanced or metastatic breast cancer (combined with endocrine therapy)
- Adjuvant treatment of early breast cancer with high recurrence risk
Mechanism of Action
Selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), disrupting cell cycle progression from G1 to S phase.
Clinical Usage Guidelines
Dosing Protocol
| Patient Type | Dosage | Duration |
|---|---|---|
| Adults (monotherapy) | 200mg twice daily | Continuous until disease progression |
| Combination therapy | 150mg twice daily + fulvestrant | 28-day cycles |
Adverse Effect Management
- Diarrhea: Implement loperamide prophylaxis
- Neutropenia: Monitor CBC every 2 weeks
- Hepatotoxicity: Monthly liver function tests
Clinical Case Studies
Case Study 1: Metastatic Breast Cancer (MONARCH 2 Trial)
Patient: 52-year-old female with HR+/HER2- metastatic breast cancer
Regimen: Abemaciclib 150mg BID + fulvestrant 500mg
Outcome: Median progression-free survival 16.4 months vs 9.3 months in placebo arm
Case Study 2: Early Breast Cancer (monarchE Trial)
Patient Cohort: 5,637 patients with high-risk early breast cancer
Regimen: Adjuvant abemaciclib + endocrine therapy
Outcome: 32% reduction in invasive disease recurrence
Contact for Pharmaceutical Procurement
For bulk orders or clinical trial supplies:
Email: info@vivalr.com
Tel: (86) 15866781826
相关产品
Chemical Name: 3-Hydroxybutyric acid
CAS No.: 625-71-8
Molecular Formula: C4H8O3
Molecular Weight: 104.1
Appearance: White powder
Chemical Name: D-PANTOTHENIC ACID
CAS No.: 79-83-4
Molecular Formula: C9H17NO5
Molecular Weight: 219.24
Appearance: Colorless or Light Yellow Oily Liquid
Chemical Name: Ethyl Hexanoate
Synonyms: Ethyl caproate; Caproic acid ethyl ester; Ethyl butyl acetate; capronic ether; hexanoic acid ethyl ester
CAS No.: 123-66-0
Molecular Formula: C8H16O2
Molecular Weight: 144.21
Chemical Name: D-PANTOTHENIC ACID
CAS No.: 79-83-4
Molecular Formula: C9H17NO5
Molecular Weight: 219.24
Appearance: Colorless or Light Yellow Oily Liquid
Chemical Name: 3-Chloroaniline
Synonyms: 1-Amino-3-chlorobenzene; m-Aminochlorobenzene; 3-Chlorobenzenamine; 3-Chlorophenylamine
CAS No.: 108-42-9
Molecular Formula: C6H6ClN
Molecular Weight: 127.57
Appearance: Colorless Liquid
Chemical Name: Di-n-amyl disulfide
Cas No.: 112-51-6
Molecular Fomula: C10H22S2
Molecular Weight: 206.41
Chemical Name: Tribehenin
Cas No.: 18641-57-1
Molecular Fomula: C69H134O6
Molecular Weight: 1059.8
Appearance: White waxy powder or solid
Chemical Name: Oxirane, methyl-, polymer with oxirane, dodecyl ether
Cas No.: 68238-81-3
Molecular Fomula: C17H36O3
Molecular Weight: 288.46594
Chemical Name: 1-[9-ethyl-6-(4-fluoro-benzoyl)-9H-carbazol-3-yl]-ethanone
Cas No.: 876907-97-0
Molecular Fomula: C23H18FNO2
Molecular Weight: 359.39
Chemical Name: alpha-Hexylcinnamaldehyde
CAS No.: 101-86-0
Molecular Formula: C15H20O
Molecular Weight: 216.32
Appearance: Yellow Liquid
Chemical Name: STODDARD SOLVENT
CAS No.: 64742-88-7
Appearance: Colorless or Light Yellow Liquid
Chemical Name: D-Phenothrin
CAS No.: 26046-85-5
Molecular Formula: C23H26O3
Molecular Weight: 350.45
Appearance: Oil
评论
目前还没有评论。